TROY, N.Y. — Researchers at Rensselaer Polytechnic Institute (RPI) and Albany College of Medicine are using artificial intelligence (AI) to improve targeted drug therapy in the treatment of HER2-positive breast cancer, from the National Cancer Institute. Received $3.3 million in annual grants. HER2-positive breast cancer tends to grow and metastasize rapidly, but targeted therapy improves outcomes.
The research was led by Xavier Intes, Rensselaer Professor of Biomedical Engineering and Co-Director of the Center for Medical Modeling, Simulation and Imaging, and Margarida Barroso, Professor of Molecular and Cellular Physiology and Director of the Imaging Core Facility in Albany. I’m here. medical college. Supported by six major grants, RPI and Albany College of Medicine have been collaborating continuously for more than a decade focused on treatments that improve human health. This grant promotes collaboration using the latest AI tools.
Targeted agents are an important part of many cancer treatments to increase specificity and reduce negative side effects. However, resistance to targeted therapies often develops, preventing long-term disease-free survival for many patients.
Officials said the grant supports intratumor heterogeneity (ITH), in which cells within the same tumor have different profiles, and microenvironmental factors are proposed to play an important role in treatment failure in HER2-positive breast cancer. said it would fund research in A deeper understanding of the mechanisms underlying HER2 therapy resistance and their relationship to ITH and the host and tumor microenvironment is therefore essential for the development of new strategies to improve patient outcomes.
There is a lack of preclinical longitudinal noninvasive imaging approaches that can analyze and quantify heterogeneity at the level of multiple tumor features such as drug-HER2 binding, glucose metabolism levels, and vasculature. Currently, these parameters can only be assessed by extracorporeal invasive means using tissue resected from and returned to the patient.
“Through our study, we developed a novel mesoscopic and multimodal preclinical imaging approach to test the hypothesis that the distribution of antibody-based therapeutics across tumors mediates not only drug efficacy but also the emergence of tumor resistance. We will,” Intes said in a news release. from university.
The research team plans to use mesoscopic fluorescence molecular tomography (MFMT) to analyze tumor heterogeneity at near-cell-scale resolution in live, intact animals.
Barroso will also work with Sandra Singh, M.D., Director of Pathology and Laboratory Medicine at Albany Medical Center to link histopathology with these new optical imaging approaches.
“Ultimately, this imaging technology will allow biologists and clinicians to see exactly how drugs bind to tumors, and how tumors adapt or change during treatment. I hope that we will be able to understand it better,” Barroso said. “This could help determine the effectiveness of specific drugs against specific tumors, a key component in tackling drug resistance.”
“For more than a decade, NCI has recognized the importance of cross-institutional collaboration and the unique skills and expertise that each investigator brings to the collaboration,” said Alan S. Bouros, M.D., Ph.D., Lynn. Dean Mark Groban, M.D., added. of Albany Medical College. “The research supported by this new grant will have a major impact on the future of cancer diagnosis and treatment.”
“We all know that there are people living with breast cancer because it is such a prevalent disease,” said Shekhar Garde, dean of the Rensselaer School of Engineering. “I am pleased that the doctors have done so. Intes and Barroso are combining the power of engineering and medicine with the latest artificial intelligence tools to advance our understanding of this particularly virulent form and help patients improve the quality of life of